Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Debt Ratio (2019 - 2025)

BridgeBio Pharma's Debt Ratio history spans 7 years, with the latest figure at 0.6 for Q4 2025.

  • For Q4 2025, Debt Ratio rose 1.71% year-over-year to 0.6; the TTM value through Dec 2025 reached 0.6, up 1.71%, while the annual FY2025 figure was 0.6, 1.71% up from the prior year.
  • Debt Ratio for Q4 2025 was 0.6 at BridgeBio Pharma, up from 0.59 in the prior quarter.
  • Across five years, Debt Ratio topped out at 0.87 in Q2 2023 and bottomed at 0.09 in Q1 2021.
  • The 5-year median for Debt Ratio is 0.58 (2022), against an average of 0.53.
  • The largest annual shift saw Debt Ratio skyrocketed 518.25% in 2022 before it plummeted 37.32% in 2024.
  • A 5-year view of Debt Ratio shows it stood at 0.43 in 2021, then skyrocketed by 62.65% to 0.69 in 2022, then grew by 18.12% to 0.82 in 2023, then fell by 27.43% to 0.59 in 2024, then increased by 1.71% to 0.6 in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Debt Ratio are 0.6 (Q4 2025), 0.59 (Q4 2024), and 0.66 (Q3 2024).